We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes (Nexium)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 18, 2008
Last Update Posted: September 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Novo Nordisk A/S
Chr Hansen
Statens Serum Institut
Steno Diabetes Center
Information provided by (Responsible Party):
Lise Tarnow, Steno Diabetes Center

To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients.

Study Hypothesis:

  1. Nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of HbA1c
  2. Probiotics changes the gut flora and bloodpressure
  3. Probiotics causes a change in inflammation and thrombosis.

Condition Intervention Phase
Type 2 Diabetes Drug: nexium Dietary Supplement: Yoghurt Drug: placebo+placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Nexium and Cardi-04 Yoghurt on Insulin Secretion and Effect and Cardi Vascular Risk Factors Associated With the Insulin Syndrome in Patients With Type 2 Diabetes - a Randomized Double-blind, Prospective, Placebo Controlled 2 x 2 Factorial Design 3 Month's Study.

Resource links provided by NLM:

Further study details as provided by Lise Tarnow, Steno Diabetes Center:

Primary Outcome Measures:
  • insulin secretion [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • blood pressure [ Time Frame: 1 year ]

Enrollment: 41
Study Start Date: June 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nexium + Yoghurt Drug: nexium
40 mg once daily is tested together with Yoghurt
Placebo Comparator: Nexium + Placebo Drug: nexium
nexium and placebo are tested
Placebo Comparator: Placebo+ Yoghurt Dietary Supplement: Yoghurt
Placebo Comparator: placebo+placebo Drug: placebo+placebo
placebo and placebo are tested.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes (WHO criteria) treated with metformin and/or sulfonylureas or diet
  • Males and females between 40 and 70 years
  • HbA1c between 6,0-10,0
  • Diabetes duration > 1 year

Exclusion Criteria:

  • Kidney disease (s-creatinine above the upper limit of normal range).
  • Liver disease (ALAT increase > 3 times the upper limit of the normal range of ALAT).
  • Macroalbuminuria (urinary albumin excretion of > 300 mg/day).
  • Heart failure(NYHA class lll or lV)
  • Severe neuropathy (symptoms + vibration perception threshold > 50 measured by biothesiometer.)
  • Neutropenia (neutrophil count<2.0x10/l) or anemia (hemoglobin<8mM for men or <7mM for women.
  • Alcohol abuse
  • Drug abuse
  • Severe organic or metabolic diseases including cancer
  • C-peptide< 0,3 pmol/l
  • Medicine interaction
  • Treatment with insulin
  • PPI or other medications for ulcus diseases
  • Treatment with warfarin or other coumarin derivations
  • Pregnant or breastfeeding women
  • Allergy to medication used in the study
  • Participants may not participate in another clinical intervention trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00699426

Sponsors and Collaborators
Lise Tarnow
Novo Nordisk A/S
Chr Hansen
Statens Serum Institut
Steno Diabetes Center
Principal Investigator: Allan A. Vaag, MD, DMSc Steno Diabetes Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lise Tarnow, professor, Steno Diabetes Center
ClinicalTrials.gov Identifier: NCT00699426     History of Changes
Other Study ID Numbers: EudraCT: 2007-00405237
First Submitted: June 16, 2008
First Posted: June 18, 2008
Last Update Posted: September 3, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action